CEPI has invested an initial $4.9 million USD for its development. ABL has been chosen by Themis to manufacture clinical trial supplies of its COVID-19 vaccine candidate in France.

May 11 (Reuters) - THEMIS BIOSCIENCE BV:Google pushes global agenda to educate workers, lawmakers on AI Technology · January 25, 2025 · 9:22 AM PST · 31 min ago Google already faces a ...